EDGAR·FLOW

ADARx Pharmaceuticals, Inc. — Form 4

Filed September 30, 2026 · analyzed by the Insider Agent
4 ▲ Likely positive significance 78/100
What the filing says
Director GORDON CARL L (ADRX) bought 24.2M shares (~$16.1M) on the open market (98% of holdings). Open-market insider purchase — historically a bullish signal.
Why this rating

Open-market insider purchase — historically a bullish signal.

Tradability signal
NO TRADE

No trade: positive news with only +3.8% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.33% over 4 hrs, n=139). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$19.97 ▼ 1.84%
at our read · unknown
$20.34
+10 min · unknown
$20.31 ▼ 0.17%
+30 min · unknown
$20.04 ▼ 1.52%
+1 hr · unknown
$20.34 ▼ 0.02%
+4 hrs · unknown
$19.70 ▼ 3.17%

The stock had already moved +1.88% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ ADRX · stock on Yahoo Finance ↗

See more from September 30, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.